Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Screening and Prostate-Cancer Mortality in a Randomized European Study
3.997
Zitationen
23
Autoren
2009
Jahr
Abstract
PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis. (Current Controlled Trials number, ISRCTN49127736.)
Ähnliche Arbeiten
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 · 5.710 Zit.
Decision Curve Analysis: A Novel Method for Evaluating Prediction Models
2006 · 5.209 Zit.
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 · 4.552 Zit.
Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer
1998 · 4.499 Zit.
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
2004 · 3.684 Zit.
Autoren
- Fritz H. Schröder
- Jonas Hugosson
- Monique J. Roobol
- Teuvo L.J. Tammela
- Stefano Ciatto
- Vera Nelen
- Maciej Kwiatkowski
- Marcos Lujan
- Hans Lilja
- Marco Zappa
- Louis Denis
- Franz Recker
- Antonio Berenguer
- Liisa Määttänen
- Chris H. Bangma
- Gunnar Aus
- Arnauld Villers
- Xavier Rebillard
- Theodorus van der Kwast
- B. G. Blijenberg
- Sue M. Moss
- Harry J. de Koning
- Anssi Auvinen
Institutionen
- Erasmus MC(NL)
- Sahlgrenska University Hospital(SE)
- Tampere University(FI)
- Tampere University Hospital(FI)
- Provincial Institute for Hygiene(BE)
- Kantonsspital Aarau(CH)
- Hospital Universitario de Getafe(ES)
- Lund University(SE)
- Memorial Sloan Kettering Cancer Center(US)
- Malmö University(SE)
- Finnish Cancer Registry(FI)
- Centre Hospitalier Universitaire de Lille(FR)
- Clinique du Millénaire(FR)
- Tampere University(FI)